|Bid||19.50 x 1000|
|Ask||19.52 x 900|
|Day's Range||19.36 - 19.64|
|52 Week Range||10.86 - 23.91|
|Beta (5Y Monthly)||1.94|
|PE Ratio (TTM)||8.26|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Denny Lanfear has been the CEO of Coherus BioSciences, Inc. (NASDAQ:CHRS) since 2010, and this article will examine...
The biosimilar leader crushed it during the first half of 2020. Will it finally earn a higher market valuation?
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 169.23% and 35.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?